7 Top AI Biology Companies to Watch in 2026

You're at the bench, the protocol is moving faster than the notebook, and the details that matter most are the ones easiest to lose, the exact timing of a spin, the order of additions, the odd color shift nobody planned for, the decision to repeat a control before lunch. That gap between doing the science and documenting the science is where a lot of useful context slips away. The strongest ai biology companies are trying to close that gap at very different layers of the workflow, from protein design to clinical intelligence to the quieter problem of better record capture. For a scientist, the primary question is not which platform sounds smartest, but which one best fits the way work happens at the bench, in the wet lab, and in the review loop afterward. For background reading on adjacent lab automation systems, see browse robotics training data for thermal cycler.

Table of Contents

• 1. Generate:Biomedicines
  • Clinical-stage protein design with a broad platform
• 2. Absci
  • Antibody design that stays close to wet-lab validation
• 4. Recursion Pharmaceuticals
  • Industrialized phenomics with large-scale automation
• 4. Recursion Pharmaceuticals
  • Industrialized phenomics with large-scale automation
• 5. Tempus AI
  • Clinical data depth for precision medicine workflows
• 6. Ginkgo Bioworks
  • Foundry-style organism engineering and deployed automation
• 7. Terray Therapeutics
  • Closed-loop chemistry for small-molecule optimization
• 7 AI Biology Companies Compared
• From Macro AI to Micro-Level Capture Closing the Data Loop

1. Generate:Biomedicines

Generate:Biomedicines sits in the part of the field that draws the most attention, de novo protein design. It's a clinical-stage company built around a Generative Biology platform, and that matters because it's not just talking about model outputs. It's trying to turn generated sequences into measurable wet-lab reality, then push the best candidates toward the clinic. The company's own site makes the platform easy to explore through the Generate:Biomedicines homepage.

Clinical-stage protein design with a broad platform

The practical appeal for a bench scientist is the tight connection between sequence generation, measurement, and developability. A lot of AI biology hype stops at “we designed a protein.” That's not useful unless the platform also tells you whether the construct behaves like something you would want to make, purify, and develop. Generate's positioning suggests an integrated loop built on large protein sequence and structure corpora plus proprietary wet-lab data, which is the right direction for teams that care about turning ideas into testable molecules.

The trade-off is access. This is not a self-serve tool for a graduate student who wants to try a few sequences before an afternoon lab meeting. It's a partnership-oriented company with limited public detail on pricing and external benchmarking, so outside teams mostly evaluate it through business development and disclosed pipeline activity. That makes sense for a company operating at clinical depth, but it also means scientists should separate platform promise from practical usability.

Practical rule: if a platform can't show how it measures function and developability, it's still an idea, not a lab tool.

Generate is most compelling for organizations that already know how to run serious protein work and want an AI partner with enough wet-lab muscle to validate what the model proposes. It's less compelling for teams that need immediate hands-on software. For those teams, the important question is whether the platform's internal data generation and validation engine is strong enough to reduce the number of dead-end constructs entering the bench queue.

2. Absci

Absci is one of the clearest examples of an AI biology company organized around a specific lab problem, full-length antibody design. That focus helps. In biologics work, the hard part is rarely generating a sequence on paper. The hard part is making a candidate that still behaves after expression, assay work, and developability screening. Absci's public story centers on its Origin-1 generative AI system and an in-house validation loop, and the company's website lays out the platform on the Absci homepage.

Antibody design that stays close to wet-lab validation

The strongest part of Absci's model is its emphasis on design-build-test cycles measured in weeks, not months. In a real lab, speed only matters if it tightens the feedback loop between hypothesis and result. A shorter cycle helps teams see earlier which sequence families deserve another round and which ones should leave the queue before they consume bench time. That is why the pairing of generative design with wet-lab validation matters more than any single model architecture.

The trade-off is clear. Partnership-first access means most researchers will not use Absci like a normal software platform. If a team wants a clickable dashboard and immediate exploration, this is probably not the right fit. It works better as a biologics engine for discovery partnerships than as a generic AI workbench.

For scientists who want a broader view of how these systems connect across discovery workflows, learn more about biology AI integration.

A practical way to evaluate Absci is to ask three questions:

• Can the team move from design to tested construct quickly enough to matter? The answer depends on how tightly the wet lab is wired into the platform.
• Does the platform stay focused on antibodies and biologics? Yes, and that focus helps antibody-heavy organizations.
• Can external scientists inspect enough of the process to trust the output? Public visibility is more limited than the platform ambition, so trust has to be built through collaboration.

For scientists who work in antibody discovery, that specialization is a strength. It keeps the platform closer to the actual grind of biologics development and further from broad “AI for biology” messaging.

4. Recursion Pharmaceuticals

Recursion Pharmaceuticals is the scale monster in this group. Its pitch is built around an end-to-end platform, Recursion OS, and an industrial lab system that generates large amounts of biological data. The company's website presents that platform clearly on the Recursion Pharmaceuticals homepage. For scientists, the interesting part is not the branding. It is the attempt to make drug discovery feel more like a data-rich operating system than a set of disconnected assays.

Industrialized phenomics with large-scale automation

Recursion's real strength is not a single model. It is the combination of automated high-throughput labs, multimodal data, and a discovery stack that connects target identification through development. That matters because many AI biology companies still struggle to close the loop between prediction and execution. Recursion is trying to own the execution layer too, which makes its system more convincing than model-only competitors. For teams trying to understand how that kind of lab infrastructure supports real discovery throughput, explore automated lab equipment workflows.

One thing that separates it from most of the field is the sheer volume of experimentation. Business coverage has described the sector moving from zero clinical programs at the start of 2020 to 30 drugs in human testing across eight well-funded companies (Business Insider's AI-biotech tally), and Recursion sits inside that broader shift from pilot work to systems that can support translational pressure. That matters in practice because a platform only earns trust when it can keep producing data that changes what gets tested next.

For a bench scientist, the trade-off is straightforward. Recursion's scale can be an advantage if your team needs disciplined assay execution, standardized data capture, and a tighter link between screening and decision-making. It is less appealing if your group wants a lightweight tool that a few scientists can use casually between experiments. Large automation stacks also bring their own overhead, because the value comes from operating the system well, not from having it.

A practical way to judge Recursion is to ask whether its workflow fits the realities of your own lab. If your team already has strong assay design and needs a more industrial way to run phenotypic screens, the platform makes sense. If your bottleneck is basic experimental coordination, the system may be more than you need. The company's real differentiator is that it treats biology as an execution problem as much as a modeling problem.

4. Recursion Pharmaceuticals

Recursion Pharmaceuticals is the scale monster in this group. Its pitch is built around an end-to-end platform, Recursion OS, and an industrial lab system that generates enormous amounts of biological data. The company's website presents that platform clearly on the Recursion Pharmaceuticals homepage. For scientists, the interesting part isn't the branding. It's the attempt to make drug discovery feel more like a data-rich operating system than a collection of disconnected assays.

Industrialized phenomics with large-scale automation

Recursion's real strength is not a single model. It's the combination of automated high-throughput labs, multimodal data, and a discovery stack that connects target identification through development. That matters because many AI biology companies still struggle to close the loop between prediction and execution. Recursion is trying to own the execution layer too, which makes its system more convincing than model-only competitors.

One thing that separates it from most of the field is the sheer volume of experimentation. Business coverage has described the sector moving from zero clinical programs at the start of 2020 to 30 drugs in human testing across eight well-funded companies (Business Insider's AI-biotech tally), and Recursion is part of that broader shift from pilot to actual clinical programs. That doesn't mean every model works. It means the field has crossed the line where AI is no longer just an internal R&D story.

The downside is access. Recursion is primarily a partnership platform, not a self-serve environment for outside researchers. Its phenomics-centric approach is powerful, but it still needs external proof across diverse targets. That's not a flaw so much as a reminder that massive data systems can be very good at certain biology and less transferable than they first appear.

Practical rule: if the platform can't tell you how its imaging or omics signal changes the next experimental decision, the scale is mostly decorative.

Recursion is worth watching because it industrializes the discovery loop itself. That makes it relevant to anyone who cares about data-rich biology, automated experimentation, and what it takes to move from isolated assays to a continuous decision engine.

5. Tempus AI

Tempus AI is not a basic protein design company, and that's exactly why it matters in this list. Its center of gravity is precision medicine, especially oncology, where biological data is tied to clinical action in a way basic research tools rarely achieve. The company's public platform is available through the Tempus homepage. For scientists who work near translational pipelines, Tempus is interesting because it treats molecular and clinical data as one operational system.

Clinical data depth for precision medicine workflows

Tempus's practical strength is the depth of its molecularly anchored patient data. That gives it value in workflows where researchers need to connect diagnostics, treatment patterns, and evidence generation. In a wet-lab context, the lesson is clear. AI biology companies that sit close to actual patient flow often have a stronger evidence base than platforms built entirely on synthetic or early discovery data.

The company also looks different from the purely experimental players because it lives in the clinical world. That means it has to support real workflows, not just demo science. For provider-facing teams and researchers operating in oncology, that can be a major advantage. It can also narrow its relevance. Tempus is less useful for a team trying to design proteins or explore broad discovery questions unrelated to care delivery.

The compliance angle matters here. Tempus works in a space where privacy, regulated records, and data handling can't be afterthoughts. For teams thinking about documentation and traceability, the Verbex article on data security and compliance is a useful complement because it addresses the practical side of handling sensitive scientific records without pretending that every workflow is the same.

Tempus also benefits from being publicly listed, which gives outsiders more visibility than they get from many private companies in this category. That doesn't make it automatically better, but it does make it easier to evaluate. For scientists who care about deployment in real care settings, that transparency counts.

6. Ginkgo Bioworks

Ginkgo Bioworks sits at the broad end of this group. It combines cell programming, automation, bioinformatics, and AI-guided design in a foundry-style model that can be applied across several sectors. Its public site is the clearest place to start for a broad view, through the Ginkgo Bioworks homepage. From a bench scientist's perspective, the question is whether that breadth gives a team more room to work or makes scoping harder.

Foundry-style organism engineering and deployed automation

The most practical reason to look at Ginkgo is its willingness to bring workflows into customer environments. That makes it more than a model company. It operates more like a systems integrator for biology, which matters when the problem is not only prediction but making a workflow run reproducibly in a real lab. Its offerings around antibody developability, perturbation-response profiling, and screening also show that the company is trying to connect AI to executable lab work, not just analysis.

That breadth has a clear upside. A team working in biologics, enzymes, or synbio can reuse infrastructure thinking and borrow methods across projects. The downside is just as real. This is a bespoke, service-heavy business, so small teams may find the scope expensive, and the outcome depends heavily on how well the collaboration is scoped. The value comes from the joint work, not from a plug-and-play product.

A second useful lens is history. Market coverage notes that demand in the related life-sciences market has been concentrated among pharmaceutical and biotechnology firms, which helps explain why companies like Ginkgo can win large, customized engagements. The buyers who need biologically integrated automation are already among the most operationally demanding.

Ginkgo fits teams that need an execution partner with strong automation reach. It is less attractive if the need is a narrow software tool for individual scientists at the bench.

7. Terray Therapeutics

Terray Therapeutics is one of the more interesting companies in the list because it ties AI directly to chemistry throughput. Its EMMI platform, short for Experimentation Meets Machine Intelligence, is built around closed-loop small-molecule discovery. The company's site is available at the Terray Therapeutics homepage. For bench scientists, the appeal is straightforward. It treats chemistry as a system where the model gets better because the lab keeps feeding it real results.

Closed-loop chemistry for small-molecule optimization

Terray is strongest where structure-activity relationship work is slow and laborious. Its TerraBind model and high-throughput experimentation loop are aimed at speeding lead optimization, which is one of the most unforgiving parts of discovery. If a team spends too long chasing incremental analogs, a platform that shortens the loop can save serious experimental effort.

The practical advantage is the feedback mechanism. A model that updates continuously from automated experimentation is more useful than a model that just predicts once and waits for someone to manually close the loop later. That difference matters in chemistry, where the sequence of decisions often matters as much as the first prediction.

The limitation is modality. Terray is a small-molecule company. That means it's less relevant for de novo protein design or broader biology platforms. It's also partnership-driven, so outside access is not the same as using a software app. Scientists should think of it as an engineered discovery engine, not a benchside tool.

The best closed-loop systems don't celebrate the model. They shorten the time between a chemical hypothesis and the next real measurement.

Terray's transparency is a plus. The company shares technical details through its blog and news flow, which helps buyers judge whether the platform is doing what it claims. That kind of disclosure is useful in a field where “AI-powered” can mean almost anything. For teams optimizing small molecules, Terray is one of the more concrete options in a crowded and often vague category.

7 AI Biology Companies Compared

From Macro AI to Micro-Level Capture Closing the Data Loop

The companies above operate at a scale most bench scientists never see directly. They build models on rich datasets, run automated labs, and push discovery toward clinical and translational outcomes. But every one of those systems depends on the quality of the raw material coming from the bench, the observations, the procedural details, the exceptions, and the little decisions that never make it into a clean slide deck. If that context is weak, the model learns less than it should. If it's delayed, incomplete, or reconstructed after the fact, the experimental record loses fidelity.

That is why the documentation layer matters so much. In practice, the most valuable AI biology systems are not only the ones that design molecules or prioritize patients, but also the ones that help preserve the scientific moment while it is still fresh. The market signal is clear. AI in life sciences has already moved into a multi-billion-dollar phase, with one market study valuing it at USD 3.61 billion in 2025 and projecting growth to USD 13.64 billion by 2031 at a 24.78% CAGR (Mordor Intelligence's life sciences market study). That kind of scale only works if the underlying data keeps its integrity.

For individual scientists, a Voice-to-ELN workflow is a practical way to improve that capture layer. Verbex is built for spoken bench notes, timestamped capture, section-based organization, and human review before export. It helps researchers record experiments as they happen, organize those notes into scientific sections, and keep control of the final record, which is exactly the kind of habit that supports better contemporaneous documentation and stronger traceability.

If better AI biology depends on better inputs, then better inputs start with better bench capture. Scientists who want to reduce reconstruction errors, protect sensitive work on-device, and keep the record closer to the experiment itself can visit Verbex to see how Voice-to-ELN fits into real lab work.